Luc-André Granier M.D., Ph.D.
CEO, Medical Director and Co-Founder of Advicenne
Luc-André co-founded Advicenne in 2007 and is the Company’s CEO, Medical Director and Chairman of the Board. Luc-André is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system with more than 25 years’ experience in the pharmaceutical (Eli Lilly and Co) and biotech (Synt:em, Forenap) industries. He has overseen a large number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, mainly in the fields of pain, migraine, neuro-degenerative diseases and psychiatric disorders. He was responsible for the successful proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004.
Luc-André obtained his degree as a Doctor of Medicine and Doctor of Science (in Biochemistry and Molecular and Cellular Biology) at the Louis Pasteur University in Strasbourg, France. He is a member of several national and international scientific societies, mainly in the field of pain, epilepsy (ILAE*) and renal diseases (ASN**, IPNA ***).
* International League Against Epilepsy, **American Society of Nephrology, *** International Pediatric Nephrology Society
Director of Operations, General Manager and Co-Founder of Advicenne
Caroline co-founded Advicenne in 2007 and is the Company’s General Manager. She is responsible for the pharmaceutical development and project management of Advicenne’s pipeline. Caroline has extensive experience in research project management and in sub-contracting early stage clinical projects. Prior to Advicenne Caroline co-founded Synt:em in 1995,
Caroline co-founded Advicenne in 2007 and is the Company’s General Manager. She is responsible for the pharmaceutical development and project management of Advicenne’s pipeline.
Caroline has extensive experience in research project management and in sub-contracting early stage clinical projects. Prior to Advicenne Caroline co-founded Synt:em in 1995,
Chief Business Officer
Ludovic joined Advicenne in August 2016 as Chief Business Officer to lead global commercial and corporate developments.
He has more than 25 years experience in international R&D, business development and marketing & sales in the pharmaceutical industry. During his career, Ludovic launched more than 15 new original products for rare diseases or for highly specialized medicines.
Prior to Advicenne, Ludovic was 12 years at Shire where he served as Marketing Manager,
Business Unit Director, Marketing Director and Commercial Operations Head of France and BeNeLux,
focusing on nephrology and child psychiatry. While at Shire he was a member of the French Executive Board from 2008 to 2016.
Before that he held various managerial and leadership roles in sales, marketing and business development at L’Oréal, Servier and Laboratoires Expanscience. where he originated, signed and executed 13 partnerships (registration, commercial) in more than 20 countries.
Ludovic has a Doctorate in Pharmacy (PharmD) and a Master in Industrial Pharmacy from Lyon I University and an MBA from HEC Paris (and Mc Gill – Montreal).
Catherine Guittet, Pharmacien
Head of Clinical Operations Department
Catherine joined Advicenne in 2008 where she is responsible for clinical research, regulatory affairs and project management. Catherine has over 15 years’ experience in clinical affairs and regulatory matters. Catherine came from Merck Serono where she managed a unit dedicated to the coordination of early clinical development in Oncology and served at French biotech company Synt:em. For several years, she was Head of Patients Clinical Study Unit at SGS-Aster (a CRO). She began her career at Theraplix (Sanofi-Aventis) as Head of Project Management where she created the department.
Catherine received her Doctorate in Pharmacy (PharmD) and Ph.D. from Angers University; graduated as Clinical Investigator from Paris VII University, obtained a Pharmaco-Epidemiology Certificate from Bordeaux II University, and a Cellular Pharmacology, Pharmacogenetics and Pharmacokinetics Certificate from Paris VII University.
Nathalie Lemarié, Pharmacien
Director of Regulatory Affairs & Qualified Person
Nathalie joined the Advicenne management team in October 2012 and oversees the company’s regulatory filings, including registration and distribution. She has over 20 years’ experience in Regulatory Affairs, both in France and abroad which she acquired at Laboratoire Chauvin, France, where she was Regulatory
Affairs Manager coordinating the groups European subsidiaries and setting up European registration procedures.
Nathalie obtained her Ph.D. in Pharmacy and Masters in Company Administration at the University of Montpellier, France.
Financial & Logistics Director
Sarah Delbaere joined Advicenne in November 2013 as Financial & Logistics Director. She has more than 15 years of experience in the pharmaceutical & biotech sector having served as Finance & Administrative Director at Takeda Pharmaceuticals and Nycomed where she was responsible for finance, supply chain, legal and general administration and was involved in the merger,
and the strategic reorganization of the company. Prior to that she was at Gencell, an affiliate of Sanofi-Aventis, specialized in gene therapy and before that at Innogenetics, a Belgium biotech company listed on NASDAQ.
Sarah is a graduate in Applied Economics from the University of Antwerp in Belgium.
Julie Rachline, PhD.
Julie joined Advicenne in November 2015 to support corporate development and investor relations. A former VC, Julie invested in diverse companies such as BrainEver, HalioDx, Nanobiotix (Ticker:NANO) or Eurogentec (sold to Kaneka). She was on the board of those companies as well as Voluntis and Stimulus.
Julie has also a strong experience in executive search as she was Principal at L3S partnership and was involved in or lead recruitments in pharma, medtech, ANSM or Agence de la Biomédecine organisations.
Julie holds a Ph.D. in Neuropharmacology from Ecole Normale Supérieure and a MS from ESCP-Europe.